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Conclusion

Background

Peripheral artery disease (PAD) affects more than 200
million people worldwide and carries significant
morbidity and mortality. Endovascular treatment of
critical femoral-popliteal PAD has advanced in recent
years. Drug eluting stents (DES) and drug coated
balloons (DCB) have demonstrated improved primary
patency compared to balloon angioplasty or bare metal
stenting. The current literature lacks any long-term
direct comparison between the two modalities.

Time to Target Lesion Reintervention

Discussion

This is the first comparison of DES and DCB for femoral
popliteal PAD out to five years. Findings suggest that
DES may have a longer patency than DCB for the
treatment of PAD. No difference in mortality was seen
between the two modalities. A dedicated randomized
control study comparing DES vs DCB would be
beneficial.

Methods

• A retrospective analysis from June 2014 to June 2018
• A single high-volume center
• Reviewed all
DCB or DES for Femoral Popliteal
Interventions
• Patient medical data and lesion characteristics were
retrieved using Vascular Quality Initiative database.
• Outcomes were analyzed through December 2019
• Primary endpoint of time to clinical event driven target
lesion reintervention (TLR) and secondary endpoint of
all-cause mortality

Demographics

Results

483 patients with a total of 563 interventions met the
inclusion criteria in the designated time frame. 359 DCB
and 204 DES were performed. Of those who underwent
DCB, 132 required bailout stenting at the time of
procedure, majority for residual stenosis. For the
endpoint of TLR: DES had a higher reintervention rate
19.6% DES vs 16.2% DCB, which was not statistically
significant. In the beginning years of the study there
was significant higher use of DES with a paradigm shift
in the final three years to DCB use.
All patients
requiring TLR were examined; mean time for TLR in DES
group was 1277 days (SD 546), while DCB mean time
for maintaining patency was 904 days (SD 330.1). For
patients requiring target lesion reintervention, DES
remained patent significantly longer than those with
DCB (373 days longer on average) (p value: < 0.001).
For all-cause mortality there was no significant
difference at 50 months between DCB and DES (p
value: 0.06).

In patients who required target lesion reintervention
DES had a significantly longer length of time to
reintervention (average of 373 days), although no
difference in mortality was observed.
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